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Poster Session I S239Conclusion: The present study demonstrates that examination by
endoscopy and Lugol staining is a useful tool to detect precancerous
esophageal carcinoma. Although the direct correlation between ex-
pression of p16 and HPV infection in this study is still under study,
it suggests that HPV may be a causative pathogen of esophageal
carcinoma after allo-HCT under immunosuppressive conditions
after allo-HCT.231
AZITHROMYCIN REDUCES THE SEVERITY OF NON-INFECTIOUS LUNG IN-
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Non-infectious lung injury (NILI) after allogeneic (allo) hemato-
poetic stem cell transplantation (HSCT) significantly contributes to
morbidity and mortality and can manifest as restrictive or/and ob-
structive pulmonary function impairment. Beneficial effects of mac-
rolides on airway inflammation and pulmonary obstruction both
after allo-HSCT and solid organ transplantation (SOT) have been
described in clinical studies.We tested the role of long-term azithro-
mycin (Azi) administration in reducing the severity of NILI follow-
ing murine HSCT. Lethally (12Gy) irradiated B6D2F1 mice
received 5  10E6 bone marrow and 6  10E6 splenocytes from ei-
ther syngeneic (syn) (B6D2F1) or allo (C57BL/6) donors. One half
of allo recipients received drinking water supplemented with Azi
(1mg/ml between day 114 and day 117, 0.5mg/ml from day 118
until day1100), whereas the other half of allo and syn recipients re-
ceived water only. On day198, surviving animals were analyzed and
pulmonary function tests (PFT) were performed.
All syn animalswere alive andwithout clinical signs of graft-versus-
host disease. Azi treatment in allo recipients resulted in better overall
survival when compared to allo controls (53.3% vs. 29.4%), but did
not relate to changes in clinical weight loss, mobility, fur and skin
changes (score: 2.7 vs. 2.7). PFT, however, revealed significant
improvement in both restrictive and obstructive parameters for
Azi-treated animals when compared to allo controls (VC:
0.53460.069 vs. 0.43560.068 ml; p 5 0.034; Cchord: 0.02960.004
vs. 0.02160.002 ml/cm H2O; p 5 0.0049; FEV50: 0.44660.06 vs.
0.36960.039 ml; p 5 0.032). Moreover, Cchord and FEV50 were
not significantly different between AZI animals and syn controls.
Neutrophil countswere assessedbymyeloperoxidase (MPO) activity,
with Azi-treatment resulting in its reduction. Further, CXCL1 and
CXCL2 lung protein levels as well as IL-6 and TGFb1 levels were
significantly lower in the Azi allo group than in allo controls, whereas
no differences were seen for TNF, IFNg or CXCL9.
Our data experimentally confirm the beneficial effects of Azi on
pulmonary function impairment in allo-HSCT recipients as being
at least partially mediated through altered chemo- and cytokine ex-
pression and decreased neutrophil recruitment to the lung. They
strengthen the concept of Azi as a well-tolerated, inexpensive but
yet efficient drug in the treatment of NILI following allo-HSCT
and SOT.232
ENDOCRINE COMPLICATIONS FOLLOWING PEDIATRIC BONE MARROW
TRANSPLANTATION
Ho, J., Lewis, V., Guilcher, G., Stephure, D., Pacaud, D. University of
Calgary, Calgary, AB, Canada
Background: Pediatric bone marrow transplantation (BMT) for
various diseases can lead to endocrine system dysfunction due to
the common preparative regimens involving chemotherapy and
radiation therapy.
Objective: The primary objective of this study was to assess the
prevalence of post BMT endocrine complications in children treated
at the Alberta Children’s Hospital from 1991-2001. The secondary
objectives were to characterize the time of onset of endocrine dys-function, underlying disease processes, chemotherapy, radiation
therapy, and age at the time of BMT.
Methods: A retrospective cohort study design was used. Subjects
were included if they were less than 18 years of age at the time of their
BMT (allogeneic or autologous) at the Alberta Children’s Hospital,
the BMTwas performed between January 1, 1991 andDecember 31,
2001, the subject had follow-up through the Alberta Children’sHos-
pital for at least one year post BMT, and their charts were available
for review. Subjects were excluded if they had a pre-existing diagno-
sis of an endocrine condition under evaluation prior to their bone
marrow transplant.
Results:A total of 194 pediatric BMTprocedures were performed at
the Alberta Children’s Hospital from January 1, 1991 to December
31, 2002. Of these, 150 complete charts were available for review.
Sixty five subjects received follow up care at other centers and
were not included in this study. Therefore, a total of 85 subjects
were included in this review. The prevalences of endocrine compli-
cations identified were: primary hypothyroidism 1.2%, compensated
hypothyroidism 7.0%, hyperthyroidism 2.4%, hypergonadotrophic
hypogonadism 22.4%, abnormal bone density 2.4%, and secondary
diabetes mellitus 1.2%.
Conclusions: These findings emphasize the need to screen for en-
docrine system dysfunction, particularly hypergonadotrophic hypo-
gonadism in children who have undergone BMT. Children need to
be followed long term so that endocrine complications can be
diagnosed and treated promptly.233
VARIATION IN MANAGEMENT OF IMMUNE SUPPRESSION AFTER
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Practice variation in immune suppression (IS) liberation after allo-
geneic hematopoietic cell transplantation (HCT) is anticipated to
have important consequences, but has not been characterized to
date. We conducted a survey of transplant physician members of
the American Society for Blood andMarrow Transplantation to dis-
cern variation in IS management and attitudes toward this practice,
characterize the burden of GVHD in the setting of IS taper, and to
describe the proportion of HCT recipients who successfully liberate
from IS by 2 and 5 years. From 1,100 eligible physicians, 225 (21%)
completed the electronic survey. Practice varied according to re-
ported time of initiation of IS taper post-HCT, sequence of agents
tapered, frequency of changes, and strategy utilized; 25% reported
no consistent strategy. In the presence of post-HCT relapse, 71%
of respondents recommended stopping all IS agents, and 50% uti-
lized donor lymphocyte infusion. Confidence in therapeutic decision
making was limited:Most reported no consistent practice guidelines,
41% reported that their current IS liberation strategy is not ade-
quate, and 26% reported being either uncomfortable or very uncom-
fortable with making decisions on IS management. The majority
indicated that they could not predict who would develop GVHD
on taper of IS, and reported a resultant burden of GVHD emerging
or recurring in the setting of IS taper. In the setting of recurrent
GVHD following IS taper, therapeutic approaches differed: 44% re-
sumed the original IS agents; 73% started 1-2mg/kg of steroids; and
16% both started 1-2mg/kg steroids and added an additional sys-
temic IS agent. The potential adverse consequence of GVHD
emerging or recurring in the setting of IS taper was highlighted by
HCT physicians’ self-report of the proportion of these cases that
are not successfully treated to resolution. Projected rates of IS liber-
ation increased from 2 to 5 years post-HCT, and differed signifi-
cantly according to donor relation and stem cell source utilized
(p \ 0.05). The marked variation in practice, burden of GVHD
emerging in the setting of IS taper, and limited confidence in thera-
peutic decision making all highlight shortcomings in an essential
component of HCT physicians’ scope of practice. These findings
argue for both more rigorous study of IS liberation post-HCT and
development of evidence-based practice guidelines.
